Swiss pharmaceutical company Roche has announced that its arthritis drug RoActemra has not proven to be effective against COVID-19 in clinical trials.
The anti-inflammatory drug, which contains the active ingredient tocilizumab, did not improve the medical condition of hospitalised patients with pneumonia, nor did it lower their mortality.
However, Roche said on Wednesday it would continue a separate COVID-19 trial that would combine RoActemra with the antiviral drug remdesivir, which was originally developed against Ebola.
Scientists around the world are testing various existing medications as potential treatments against COVID-19, including treatments against HIV and multiple sclerosis.
Support PREMIUM TIMES' journalism of integrity and credibility
Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.
For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.
By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.
TEXT AD: To advertise here . Call Willie +2347088095401...